Erratum: Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids (Cell Reports (2022) 39(4), (S2211124722004946), (10.1016/j.celrep.2022.110733))

Michael R. Martino; Manuel Gutiérrez-Aguilar; Nicole K.H. Yiew; Andrew J. Lutkewitte; Jason M. Singer; Kyle S. McCommis; Daniel Ferguson; Kim H.H. Liss; Jun Yoshino; M. Katie Renkemeyer; Gordon I. Smith; Kevin Cho; Justin A. Fletcher; Samuel Klein; Gary J. Patti; Shawn C. Burgess; Brian N. Finck

doi:10.1016/j.celrep.2022.111633

Erratum: Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids (Cell Reports (2022) 39(4), (S2211124722004946), (10.1016/j.celrep.2022.110733))

Michael R. Martino, Manuel Gutiérrez-Aguilar, Nicole K.H. Yiew, Andrew J. Lutkewitte, Jason M. Singer, Kyle S. McCommis, Daniel Ferguson, Kim H.H. Liss, Jun Yoshino, M. Katie Renkemeyer, Gordon I. Smith, Kevin Cho, Justin A. Fletcher, Samuel Klein, Gary J. Patti, Shawn C. Burgess, Brian N. Finck

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

(Cell Reports 39, 110733; April 26, 2022) In the original published version of this paper, a declaration of interests was accidently omitted: “B.N.F. is a member of the scientific advisory board and has stock in Cirius Therapeutics, which is developing MPC inhibitors for clinical use.” This has been corrected online. The authors apologize for this error.

Original language	English (US)
Article number	111633
Journal	Cell Reports
Volume	41
Issue number	7
DOIs	https://doi.org/10.1016/j.celrep.2022.111633
State	Published - Nov 15 2022

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/j.celrep.2022.111633

Fingerprint

Dive into the research topics of 'Erratum: Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids (Cell Reports (2022) 39(4), (S2211124722004946), (10.1016/j.celrep.2022.110733))'. Together they form a unique fingerprint.

Cite this

Martino, M. R., Gutiérrez-Aguilar, M., Yiew, N. K. H., Lutkewitte, A. J., Singer, J. M., McCommis, K. S., Ferguson, D., Liss, K. H. H., Yoshino, J., Renkemeyer, M. K., Smith, G. I., Cho, K., Fletcher, J. A., Klein, S., Patti, G. J., Burgess, S. C., & Finck, B. N. (2022). Erratum: Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids (Cell Reports (2022) 39(4), (S2211124722004946), (10.1016/j.celrep.2022.110733)). Cell Reports, 41(7), Article 111633. https://doi.org/10.1016/j.celrep.2022.111633

Erratum: Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids (Cell Reports (2022) 39(4), (S2211124722004946), (10.1016/j.celrep.2022.110733)). / Martino, Michael R.; Gutiérrez-Aguilar, Manuel; Yiew, Nicole K.H. et al.
In: Cell Reports, Vol. 41, No. 7, 111633, 15.11.2022.

Research output: Contribution to journal › Comment/debate › peer-review

Martino, MR, Gutiérrez-Aguilar, M, Yiew, NKH, Lutkewitte, AJ, Singer, JM, McCommis, KS, Ferguson, D, Liss, KHH, Yoshino, J, Renkemeyer, MK, Smith, GI, Cho, K, Fletcher, JA, Klein, S, Patti, GJ, Burgess, SC & Finck, BN 2022, 'Erratum: Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids (Cell Reports (2022) 39(4), (S2211124722004946), (10.1016/j.celrep.2022.110733))', Cell Reports, vol. 41, no. 7, 111633. https://doi.org/10.1016/j.celrep.2022.111633

Martino MR, Gutiérrez-Aguilar M, Yiew NKH, Lutkewitte AJ, Singer JM, McCommis KS et al. Erratum: Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids (Cell Reports (2022) 39(4), (S2211124722004946), (10.1016/j.celrep.2022.110733)). Cell Reports. 2022 Nov 15;41(7):111633. doi: 10.1016/j.celrep.2022.111633

@article{2a74ae1f17de47cd9db654fae9973670,

title = "Erratum: Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids (Cell Reports (2022) 39(4), (S2211124722004946), (10.1016/j.celrep.2022.110733))",

abstract = "(Cell Reports 39, 110733; April 26, 2022) In the original published version of this paper, a declaration of interests was accidently omitted: “B.N.F. is a member of the scientific advisory board and has stock in Cirius Therapeutics, which is developing MPC inhibitors for clinical use.” This has been corrected online. The authors apologize for this error.",

author = "Martino, {Michael R.} and Manuel Guti{\'e}rrez-Aguilar and Yiew, {Nicole K.H.} and Lutkewitte, {Andrew J.} and Singer, {Jason M.} and McCommis, {Kyle S.} and Daniel Ferguson and Liss, {Kim H.H.} and Jun Yoshino and Renkemeyer, {M. Katie} and Smith, {Gordon I.} and Kevin Cho and Fletcher, {Justin A.} and Samuel Klein and Patti, {Gary J.} and Burgess, {Shawn C.} and Finck, {Brian N.}",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2022",

month = nov,

day = "15",

doi = "10.1016/j.celrep.2022.111633",

language = "English (US)",

volume = "41",

journal = "Cell Reports",

issn = "2211-1247",

publisher = "Cell Press",

number = "7",

}

TY - JOUR

T1 - Erratum

T2 - Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids (Cell Reports (2022) 39(4), (S2211124722004946), (10.1016/j.celrep.2022.110733))

AU - Martino, Michael R.

AU - Gutiérrez-Aguilar, Manuel

AU - Yiew, Nicole K.H.

AU - Lutkewitte, Andrew J.

AU - Singer, Jason M.

AU - McCommis, Kyle S.

AU - Ferguson, Daniel

AU - Liss, Kim H.H.

AU - Yoshino, Jun

AU - Renkemeyer, M. Katie

AU - Smith, Gordon I.

AU - Cho, Kevin

AU - Fletcher, Justin A.

AU - Klein, Samuel

AU - Patti, Gary J.

AU - Burgess, Shawn C.

AU - Finck, Brian N.

PY - 2022/11/15

Y1 - 2022/11/15

N2 - (Cell Reports 39, 110733; April 26, 2022) In the original published version of this paper, a declaration of interests was accidently omitted: “B.N.F. is a member of the scientific advisory board and has stock in Cirius Therapeutics, which is developing MPC inhibitors for clinical use.” This has been corrected online. The authors apologize for this error.

AB - (Cell Reports 39, 110733; April 26, 2022) In the original published version of this paper, a declaration of interests was accidently omitted: “B.N.F. is a member of the scientific advisory board and has stock in Cirius Therapeutics, which is developing MPC inhibitors for clinical use.” This has been corrected online. The authors apologize for this error.

UR - http://www.scopus.com/inward/record.url?scp=85141926820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85141926820&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2022.111633

DO - 10.1016/j.celrep.2022.111633

M3 - Comment/debate

C2 - 36384117

AN - SCOPUS:85141926820

SN - 2211-1247

VL - 41

JO - Cell Reports

JF - Cell Reports

IS - 7

M1 - 111633

ER -

Erratum: Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids (Cell Reports (2022) 39(4), (S2211124722004946), (10.1016/j.celrep.2022.110733))

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this